Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer

August 2001

Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer seem to have a higher risk of osteoporosis.

This makes sense.

These drugs slow the growth of prostate cancer by suppressing testosterone production.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cholesterol Bayer is taking Baycol (cerivastatin) off the market
new thinking on which women should take hormone replacement therapy
Gastroenterology acid blockers for some patients with irritable bowel syndrome
Cardiology measuring C-reactive protein...to help identify patients who could benefit from statins
Infectious Diseases flu vaccine delay again this year
Infectious Diseases Valtrex (valacyclovir) for just 3 days for treating recurrent genital herpes
Parkinson's Disease new treatment algorithm to select drugs for Parkinson's disease
Dermatology topical phenytoin for wound healing
Dermatology Estrostep for acne in young women
Pediatrics iron deficiency might reduce cognitive ability in school-aged kids
Osteoporosis best way to switch women from estrogen replacement therapy to Evista (raloxifene)
Osteoporosis Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer
Anticoagulants new guidelines on using low-molecular-weight heparins (Lovenox, Fragmin, Innohep)
recognizing and treating postpartum depression
stronger warnings about prescribing OxyContin
Liver Disease which drugs require liver function tests